Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
30 oct. 2024 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated...
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
29 oct. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
[Latest] Global Hydrolyzed Vegetable Protein Market Size/Share Worth USD 3,556.8 Million by 2033 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
29 oct. 2024 02h30 HE
|
Custom Market Insights
Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hydrolyzed Vegetable Protein Market Size, Trends and Insights By Source (Pea,...
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
28 oct. 2024 10h00 HE
|
HOPO Therapeutics, Inc.
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
28 oct. 2024 08h00 HE
|
Phathom Pharmaceuticals
Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
27 oct. 2024 12h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
24 oct. 2024 08h00 HE
|
Regeneron Pharmaceuticals, Inc.
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if...
Rapid Micro Biosystems to Announce Third Quarter 2024 Financial Results on November 1, 2024
23 oct. 2024 16h45 HE
|
Rapid Micro Biosystems, Inc.
LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation...
Cell Therapy Collaboration and Licensing Deals Report 2016-2024: A Comprehensive Listing of 910 Cell Therapy Deals by Company A-Z, Deal Type and Therapy Area
23 oct. 2024 12h24 HE
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Cell Therapy Collaboration and...
Rapafusyn Announces an Upcoming Oral Presentation at Targeted Protein Degradation & Induced Proximity Summit
23 oct. 2024 11h06 HE
|
Rapafusyn Pharmaceuticals
BALTIMORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce an upcoming oral presentation at the 7th Targeted Protein Degradation & Induced Proximity Summit...